vACcine Covid-19 monitoring ReadinESS
Preparing Europe and activating the infrastructure needed to monitor the benefits, coverage and safety risks of new COVID-19 vaccines
Researchers from the Netherlands are involved in a European project which aims to prepare Europe for a COVID-19 vaccine. The ACCESS project (Vaccine Covid-19 monitoring ReadinESS) is a feasibility study to prepare for monitoring the safety and effectiveness of the COVID-19 vaccines when they become available on the market.
A total of 22 European organisations are involved. The Dutch contribution is significant, as UMC Utrecht, Utrecht University, RIVM, the Netherlands Pharmacovigilance Centre Lareb and research institute PHARMO are contributing to ACCESS. The project is led by UMC Utrecht and Utrecht University.
The development of a vaccine normally takes 10 to 15 years. Because of the COVID-19 pandemic, the aim is to develop a vaccine within one year. The ACCESS project will help to prepare Europe for this undertaking.
RIVM role
RIVM is contributing to the feasibility analysis of an EU (European Union) structure for COVID-19 vaccine monitoring, in collaboration with Lareb.
Funding
ACCESS was commissioned by the European Medicines Agency (EMA) in May 2020.